NAGEHealthcare · BiotechnologyThe 6 Wall Street analysts covering Niagen Bioscience, Inc. hold a median 12-month price target of $11 — +211.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Niagen Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Momentum (7): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Niagen Bioscience, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on NAGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +211.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $11 |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | $13 → $10 |
| 31 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 5 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 June 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 June 2025 | Roth Capital | Maintains | Buy | — |
| 27 May 2025 | Canaccord Genuity | Initiates | Buy | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2025 | Ladenburg Thalmann | Maintains | Buy | — |
| 6 Nov 2024 | Roth MKM | Maintains | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 51% of US stocks
Cheaper than 30% of US stocks
Cheaper than 19% of US stocks
Higher than 37% of US stocks
Higher than 65% of US stocks
Higher than 78% of US stocks
Higher than 57% of US stocks
Higher than 77% of US stocks
Higher than 86% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAGE appears on the weeks it earns a place.
Niagen Bioscience has selected Evotec as a contract research organization to support preclinical development of NB4168, in collaboration with NAD Pharmaceuticals Corp.
Why it matters — This partnership with a global drug development firm signals progress in advancing NB4168 through preclinical stages.
Niagen Bioscience announced the publication of a peer-reviewed analysis in Aging Cell, which examined past clinical studies and found that supplementation with its patented Niagen® (nicotinamide riboside) was associated with reduced muscle epigenetic age acceleration as measured by the Muscle Epigenetic Age Test clock.
Why it matters — This publication adds peer-reviewed, independent scientific evidence supporting the company's core product and its potential impact on a biological marker of aging.
Niagen Bioscience announced that CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity's 46th Annual Growth Conference in Boston from August 11 to 13, 2026, with Mr. Fried scheduled for a fireside chat on August 11.
Why it matters — Presenting at a major industry conference signals visibility and engagement with the investment community, which NAGE watchers may track for strategic messaging.
The 6 Wall Street analysts covering Niagen Bioscience, Inc. have a median 12-month price target of $11, with estimates ranging from $8.5 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Niagen Bioscience, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Niagen Bioscience, Inc. 52 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Niagen Bioscience, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +211.6% from the last close, and Ticker Nerd's factor model ranks Niagen Bioscience, Inc. 52 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Niagen Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.5 to $22 over the next 12 months.
Niagen Bioscience, Inc. returned -61.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California.
The most recent item we track (Business Wire, 3 Aug 2026): "Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168". Niagen Bioscience has selected Evotec as a contract research organization to support preclinical development of NB4168, in collaboration with NAD Pharmaceuticals Corp.
Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California. The company specializes in advancing NAD+ science to support cellular health and healthy aging through its proprietary Niagen platform, a patented NAD+-boosting ingredient known as nicotinamide riboside (NR). Niagen powers leading brands such as Tru Niagen, an oral supplement for consumer use, and Niagen Plus, which includes pharmaceutical-grade intravenous and injectable formulations available at clinics across the U.S. Niagen Bioscience Inc. operates ISO-accredited laboratories and maintains a reference standards business providing natural products, phytochemicals, and botanical reference materials for quality assurance in food, supplements, and research. It also runs the ChromaDex External Research Program, supplying high-quality NAD+ precursors to academic and government researchers worldwide. The company discovers, develops, and commercializes proprietary ingredient technologies targeting dietary supplements, food, beverages, skin care, and pharmaceutical markets, emphasizing science-backed innovation, clinical research, and regulatory compliance.
CEO Mr. Robert N. Fried · 117 employees · United States · https://www.niagenbioscience.com